FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma

Drug

Bizengri (zenocutuzumab-zbco) · Anti-HER2-HER3 bispecific antibody

Conditions

GastrointestinalThoracic